Gilead Sciences, Inc.

Nexstar Pharmaceuticals, Inc.

David H Parma

Larry M Gold

Brian James Hicke

Philippe Bridonneau

Stephen L Warren

This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the ability to bind to the lectins, wheat germ agglutinin, L-selectin, E-selectin and P-selectin. Also disclosed are the methods for obtaining such ligands.

High affinity nucleic acid ligands to lectins

Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.

Tenascin-C nucleic acid ligands

This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the ability to bind to the lectins, wheat germ agglutinin, L-selectin and P-selectin. Also disclosed are the methods for obtaining such ligands.

Method for identification of high affinity nucleic acid ligands to

This invention discloses high-affinity oligonucleotide ligands to human secretory phospholipase A2 (sPLA.sub.2), specifically RNA ligands having the ability to bind to sPLA.sub.2, and the methods for obtaining such ligands.

Growing community of inventors

Boulder, CO, United States of America

David H Parma